tmsforacure.org



- Document List for Download
- Members

Download Printable File
PDF | Word Document
- Locations

Download Printable File
PDF | Word Document
- Definition
- Diagnosis and Classification
- Symptoms
- Treatment
- Prognosis
- Mast Cell Activation Disorders
- Sources

Download Printable File
PDF | Word Document
- Introduction
- Age of Onset
- Presentation
- Possible Symptoms/Occurance Rates
- Guidelines For Acquiring a Diagnosis
- Treatment Guidelines
- Prognosis
- References

Download Printable File
PDF | Word Document
- What Are Mast Cell Diseases?
- Avoid Triggers
- Drugs to Administer with Caution
- Anaphylaxis Severity
- Call for Help
- Epinephrine
- Bronchospasm and Angioedema
- Cardiac Arrhythmias
- Hypotension
- Continuation of Care
- Precautions For Mastocytosis
- What Else Should I Know?
- References

Download Printable File
PDF | Word Document
- Article

Download Printable File
PDF | Word Document
- Card 1 - Front
- Card 1 - Back
- Card 2 - Front
- Card 2 - Back

Download Printable File
PDF | Word Document
- Reference Articles
- Abstract - Immunotherapy
- Abstract - WHO Criteria
- Abstract - Pregnancy in Mastocytosis
- Abstract - Characteristics of Clonal MCAD
- Abstract - Background Diagnostic Criteria

Download Printable File
PDF | Word Document


Mastocytosis Explained

Prognosis

The prognosis of mastocytosis depends on the specific classification of the disease. The prognosis for cutaneous mastocytosis and indolent mastocytosis is good. Occasionally a patient with indolent mastocytosis progresses to a more severe classification, but this is unusual, especially if the diagnosis has been made for several years and the progression has not been rapid. Most patients with indolent mastocytosis will have what is probably a normal life span. The prognosis of patients with mastocytosis and an associated clonal, non-mast cell hematologic disorder depends on the prognosis of the hematologic disorder. The prognosis for aggressive mastocytosis is guarded and relies on supportive care and response to cytoreductive therapy. Mast cell leukemia has been invariably fatal within a few months to a year, though recent cases have shown a partial response to targeted therapies before a fatal relapse.

 
 
Image Use Policy  |  Privacy Policy  |  Site Map  |  Contact Info 
© 2011 The Mastocytosis Society - All Rights Reserved